CD274 and neoplasm: Many biomarkers, including tumor mutation burden, programmed cell death 1 ligand 1 (PD-L1) expression, microsatellite instability, and Epstein–Barr virus infection status, identify susceptibility to PD-1/PD-L1 inhibitors (Kim et al., 2018; McGrail et al., 2021).